What Plasma-Lyte 148 treats: main uses and benefits

Plasma-Lyte 148 solution for infusion is a multiple electrolyte injection applied in addressing fluid volume concerns and issues related to electrolyte or acid-base balance.

The solution is commonly used for fluid replacement in clinical settings. It is applied in scenarios involving acute or unstable symptom patterns associated with volume loss, such as following burns, trauma, severe infection, or during major surgery.

The solution is considered relevant when supportive symptom management is appropriate, which helps ease the overall symptom burden. Its uses include managing situations requiring rapid volume replacement, managing dehydration, and managing mild-to-moderate metabolic acidosis. This symptomatic support may help patients cope more steadily with symptom fluctuations.

“The electrolyte formulation supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.”

Quick Fact: Relief for symptoms related to systemic imbalance.

Eligibility scope

Eligibility classifications (high-level)

Resulting eligibility structure

Official eligibility statements:

• Use is contraindicated in patients with Hyperkalaemia or Alkalosis.
• Avoid or restrict use in patients with severe renal impairment, congestive heart failure, or hypermagnesemia.
• Pediatric use is not established in U.S. regulatory documentation.

Connection to the overall eligibility profile

The regulatory profile strictly defines who can and cannot use the medicine by prohibiting use in those with pre-existing electrolyte overload or acid-base imbalance ( Alkalosis) and those with impaired clearance ( Severe renal impairment). Eligibility is conditional on the patient's capacity to process the solution's components and is restricted for certain age and physiological groups.

Plasma-Lyte 148 is an electrolyte solution whose interactions are primarily pharmacodynamic, involving additive effects on electrolyte and volume balance, as documented in official prescribing information.

Official Interaction Statements

These documented interactions structure the regulatory profile around the components: potassium content, sodium content, and the metabolic alkalinizing function, establishing constraints for co-administration with other specified drug classes.

Plasma-Lyte 148 is a crystalloid solution that functions by directly supplying ions required for physiological processes. It provides key electrolytes, including sodium ( Na^+), potassium ( K^+), and chloride ( Cl^-), which rapidly integrate into the body's fluid and electrolyte homeostatic pathways to support volume status. A secondary mechanism involves acid-base balance. The solution contains the inactive ingredients acetate and gluconate, which serve as metabolizable precursors. These organic anions are taken up and processed primarily by the liver, resulting in the intracellular generation of bicarbonate ( HCO3^-). The resulting bicarbonate acts as an external buffer source, modulating the physiological buffering system to contribute to the stabilization of pH.

Official Administration Instructions for Plasma-Lyte 148

Plasma-Lyte 148 solution is for intravenous administration only, using sterile equipment. The dosage, volume, rate, and duration of the infusion must be individualized and determined by a physician, based on the patient's age, weight, and clinical condition.

Procedural Requirements

• Inspection: Before use, the solution must be visually inspected for particulate matter and discoloration. Administration must not proceed unless the solution is clear and the container's seal is intact.
• Administration Set: The container should be suspended from the eyelet support and the administration set attached using an aseptic technique. To prevent the risk of air embolism, flexible plastic containers must not be connected in series, nor should they be pressurized to increase flow rates. A non-vented administration set or a vented set with the vent closed should be used.
• Additives: If supplemental medication is deemed necessary by a physician, compatibility with Plasma-Lyte 148 must be assessed before mixing. Additives must be introduced using aseptic technique and thoroughly mixed. Solutions containing additives must be used immediately and should not be stored.
• Disposal: The contents of the container are intended for single use. Any unused portion of the solution remaining after the administration is complete must be immediately discarded.

Research evidence / Overview of studies for Plasma-Lyte 148

Studies in Hospitalized Patients with Critical Conditions

Research has explored how different intravenous fluids affect patients in intensive care or emergency departments, which are settings with varying symptom burdens. These are conditions associated with acute or disruptive episodes, and the studies were relevant in trials assessing short-term or episodic symptom patterns. Plasma-Lyte 148 was studied for how it might relate to outcomes related to systemic or functional imbalance, with particular attention to outcomes monitoring physiological strain or stress. These trials often compared this balanced electrolyte solution to a different type of fluid.

Findings from studies conducted during periods of increased symptom activity suggest that using a balanced electrolyte solution, such as Plasma-Lyte 148, was associated with certain patterns observed in the studies compared to using a different type of fluid. Some evidence suggests that for large groups of critically ill patients, research examined whether this fluid was associated with patterns related to certain kidney-related outcomes. However, the evidence is limited, and findings were mixed in some specific subgroups, meaning that certainty remains low.

Research in Non-Critical Surgical Settings

Research examined the use of Plasma-Lyte 148 in surgical contexts involving conditions marked by functional limitations and monitored outcomes reflecting daily functioning or activity level. This application was observed in research contexts involving fluctuating or unstable symptoms during and immediately following medical procedures. The studies explored short-term symptom changes and research examined temporary physiological imbalance related to surgery.

Data show patterns related to maintaining stability in certain physiological measures during surgery. This was evaluated against different fluids. Findings help contextualize how patient-reported outcomes describing perceived discomfort evolved in the short term. The research highlights changes measured during the study period, including outcomes describing episodic or acute changes.

Evidence in Patients with Specific Functional Imbalances

Plasma-Lyte 148 was evaluated in conditions where symptoms may vary in intensity and involve periods of heightened symptoms, specifically in patients with existing issues related to systemic or functional imbalance. This research often focuses on its effect on acid-base balance, which is a key physiological component that was observed in these studies. Findings indicate that the results of these studies contribute to the broader evidence landscape regarding laboratory values. Evidence quality varies across studies, and data are still emerging.

Key Studies & References Plasma-Lyte 148 Injection, Monograph (Official US Prescribing Information)

Common questions about Plasma-Lyte 148 (FAQ)

Q: Is Plasma-Lyte 148 the same as saline solution?

A: Plasma-Lyte 148 is classified as a balanced electrolyte solution, which differs from normal saline (0.9% sodium chloride). Official information indicates that it has a lower concentration of chloride and contains two buffering agents, acetate and gluconate. This specific composition is designed to closely match the electrolyte and pH profile of the body’s own plasma.

Q: What is the main difference between Plasma-Lyte 148 and Lactated Ringer's?

A: Both are balanced crystalloid solutions used for fluid replacement. A key compositional difference is the ingredient used for buffering the solution. Plasma-Lyte 148 uses acetate and gluconate as precursors for bicarbonate, whereas Lactated Ringer's solution uses lactate as its precursor to help maintain the body's acid-base balance.

Q: What happens if Plasma-Lyte 148 is given too fast?

A: The official prescribing information notes that administration can lead to fluid and/or solute overload. This may result in overhydration (hypervolemia) or congested states, potentially causing swelling in the lungs or extremities. The prescribing information emphasizes that the rate of infusion is highly individualized and determined by a physician.

Q: What are the symptoms of too much Plasma-Lyte 148 being administered?

A: The documented risk associated with over-administration is fluid and solute overload (hypervolemia). Symptoms that may be related to this condition include swelling in the arms or legs, significant weight gain, or feelings of shortness of breath. Official administration instructions note that the infusion should be discontinued if an adverse reaction or sign of overload occurs.

Q: Can Plasma-Lyte 148 affect blood sugar levels?

A: The base Plasma-Lyte 148 solution does not contain glucose (sugar). However, a separate official formulation that includes 5% Glucose is available. For that specific combination, official information indicates that blood sugar levels may require monitoring in patients receiving the glucose formulation, especially in patients with diabetes.

Q: Why would someone feel sick after getting an IV fluid like Plasma-Lyte 148?

A: Official safety data documents several adverse reactions that may cause general discomfort or sickness. These include chills, a febrile response (fever), a general feeling of weakness, or hypersensitivity reactions. Specific administration-related issues like pain at the infusion site are also documented.

Q: What does the '148' in Plasma-Lyte 148 refer to?

A: Authoritative reviews state that the number 148 refers to the total concentration of the major positively charged ions (cations) in the solution. This number represents the combined concentration of sodium, potassium, and magnesium in millimoles per liter ( mmol/L), which is formulated to be similar to the concentration found in human blood plasma.

Q: Where in the body does Plasma-Lyte 148 go after it's administered?

A: Plasma-Lyte 148 is a crystalloid solution that is administered into the vein (intravenously). Official documents describe its function as a volume replacement agent. The solution’s components quickly distribute from the bloodstream to the interstitial space—the fluid surrounding the body's cells—to help restore overall fluid balance.

Q: Can Plasma-Lyte 148 cause swelling in the hands or feet?

A: Fluid and solute overload is a documented risk associated with the solution. Swelling in the hands or feet, medically known as peripheral edema, is a recognized potential sign related to fluid retention or fluid imbalance.

Q: Are headaches a known side effect of Plasma-Lyte 148?

A: Headache is not listed as a common, standalone adverse reaction in the safety documents. However, severe headache may be a symptom of a serious electrolyte imbalance, such as acute hyponatremic encephalopathy, which is a documented risk of large-volume administration.

Q: How often is Plasma-Lyte 148 given?

A: Regulatory documents state that the dosage, rate, and duration of the infusion are highly individualized and must be determined by a physician based on the patient’s clinical status. The solution is not given on a fixed, universal schedule.

Q: Does Plasma-Lyte 148 affect urine output?

A: Official information indicates that the solution is capable of inducing diuresis (increased urine output) depending on the patient's fluid status. Because its function is to restore fluid volume and mineral balance, it can help stabilize or increase urine output.

Q: Is Plasma-Lyte 148 commonly used in operating rooms?

A: Yes, official indications for the solution include its use as an intraoperative fluid replacement. This confirms its intended role for replacing fluid lost during surgical procedures.

Q: Is Plasma-Lyte 148 safe for people with kidney issues?

A: The solution is contraindicated in patients with severe renal impairment (kidney failure). This is due to the risk of retaining the solution’s components, such as sodium or potassium. For those with diminished renal function, official documents advise great caution.

Q: What is the pH level of Plasma-Lyte 148?

A: The solution is typically formulated to a pH of approximately 7.4, which is considered physiological. This level is designed to support the solution's function as a balanced electrolyte agent.

Q: Are there different versions or strengths of Plasma-Lyte 148?

A: Official labeling and product information indicate that a version of the solution is available with 5% Dextrose (Glucose), in addition to the base Plasma-Lyte 148 solution without dextrose.

Q: Are there any long-term side effects noted for Plasma-Lyte 148?

A: Regulatory documents classify potential adverse reactions primarily within the context of administration and fluid balance, focusing on risks like fluid overload and electrolyte disturbances. The documented safety profile does not specifically categorize or address effects using the term 'long-term.'

Q: Does Plasma-Lyte 148 have any calories?

A: The solution does contain a small amount of energy. One liter of Plasma-Lyte 148 solution contains approximately 66 kilojoules (or 15.7 calories), which comes from the metabolizable precursors (acetate and gluconate) included in the formulation.

How to Store and Dispose of Plasma-Lyte 148

Official regulatory documents detail specific conditions required for the storage and handling of Plasma-Lyte 148 solution.

Storage Requirements

Disposal

Any unused portion of Plasma-Lyte 148 solution, including residual contents in a partially used container or a damaged unit, must be discarded. Disposal should be carried out according to standard procedures for unused pharmaceutical products.